PKMYT1 & WEE1 Assay
Oncology
CommercialAvailable
Key Facts
About Aurora Biolabs
Aurora Biolabs operates as a premier manufacturer and service provider in the life sciences research tools sector, focusing on enabling drug discovery through reliable, ISO 17025-certified reagents and assays. As a subsidiary of Structure Based Design, Inc. (SBD), it leverages decades of scientific expertise to offer assay development, protein expression, and a 145K-compound library screening service. The company is strategically positioned as a direct US manufacturer, ensuring quality control and cost-effective solutions for academic, biotech, and pharmaceutical research clients.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | coherent-biopharma | IND-enabling |
| Bi-XDC with RPT | coherent-biopharma | Early-stage |
| mRNA Anticancer Vaccine | sunshine-biopharma | Preclinical Research |
| Biosimilar Bevacizumab | organon-2 | Phase 3 |
| Biosimilar Pembrolizumab | organon-2 | Phase 3 |
| BCL-2 Inhibitor Program | vincerx-pharma | Preclinical |
| Not specified in provided content | 3sbio | Various |
| Preclinical Projects | zion-pharma | Preclinical |
| Attenukine Oncology Candidate | teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | xema-group | Commercial |
| KRAS inhibitor | risen-pharma-tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |